Pyxis Oncology is trading 8.74% down at $3.55 after releasing updated Phase 1 monotherapy data for MICVO in recurrent/metastatic head and neck cancer following its September 9, 2026 webcast. - Among 33 evaluable patients, confirmed objective response rate was 36%, disease-control rate was 94%, and median progression-free survival was 6.2 months. - Safety included 54.3% Grade 3-or-higher treatment-related adverse events and 40% dose reductions.